Your browser is no longer supported. Please, upgrade your browser.
Settings
ETNB 89bio, Inc. daily Stock Chart
ETNB [NASD]
89bio, Inc.
Index- P/E- EPS (ttm)-4.96 Insider Own- Shs Outstand13.79M Perf Week2.86%
Market Cap505.63M Forward P/E- EPS next Y-4.49 Insider Trans- Shs Float3.80M Perf Month-5.53%
Income-63.50M PEG- EPS next Q-0.84 Inst Own85.20% Short Float3.57% Perf Quarter0.16%
Sales- P/S- EPS this Y-210.60% Inst Trans0.15% Short Ratio1.43 Perf Half Y20.24%
Book/sh5.79 P/B5.40 EPS next Y-28.30% ROA- Target Price49.57 Perf Year-
Cash/sh5.28 P/C5.91 EPS next 5Y13.00% ROE- 52W Range14.00 - 47.25 Perf YTD18.87%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-33.87% Beta-
Dividend %- Quick Ratio11.20 Sales past 5Y- Gross Margin- 52W Low123.21% ATR3.14
Employees17 Current Ratio11.20 Sales Q/Q- Oper. Margin- RSI (14)52.29 Volatility8.10% 8.63%
OptionableNo Debt/Eq0.00 EPS Q/Q-107.80% Profit Margin- Rel Volume0.54 Prev Close30.01
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume95.37K Price31.25
Recom1.70 SMA20-1.49% SMA5012.88% SMA20013.27% Volume53,670 Change4.13%
Jul-31-20Initiated Piper Sandler Overweight $54
Jul-23-20Initiated BTIG Research Buy
Jul-07-20Initiated Chardan Capital Markets Buy $58
Dec-09-19Initiated SVB Leerink Outperform
Dec-09-19Initiated RBC Capital Mkts Outperform
Dec-09-19Initiated Oppenheimer Outperform
Dec-09-19Initiated BofA/Merrill Neutral
Aug-03-20 04:05PM  
Jul-24-20 06:12PM  
Jul-13-20 10:18AM  
Jul-10-20 08:26AM  
Jul-07-20 09:30PM  
Jul-06-20 06:30AM  
Jun-04-20 08:00AM  
May-27-20 05:26PM  
May-13-20 04:05PM  
May-08-20 07:30AM  
Apr-13-20 08:30AM  
Mar-25-20 04:05PM  
Mar-18-20 04:05PM  
Feb-21-20 04:05PM  
Feb-11-20 06:43AM  
Dec-18-19 04:05PM  
Nov-13-19 04:02PM  
Nov-11-19 09:25AM  
08:22AM  
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is BIO89-100, an engineered glycoPEGylated analog of fibroblast growth factor 21 that is in proof of concept Phase 1b/2a clinical trial in patients with nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver diseases with a high risk of NASH. 89bio, Inc.was founded in 2018 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Longitude Capital Partners III10% OwnerJul 10Buy27.50109,0902,999,9752,600,877Jul 14 08:11 PM
Grunberg GregoryDirectorJul 10Buy27.50109,0902,999,9752,600,877Jul 14 08:08 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJul 08Buy27.50275,0007,562,5003,436,214Jul 10 04:32 PM